Bayer/J&J eye new paediatric use for anticoagulant Xarelto

Bayer and Johnson & Johnson’s Xarelto (rivaroxaban) has been shown to prevent recurrence of thromboembolism in children, paving the way for a potential new indication for the anticoagul

UK biotech PhoreMost to work with India's CCBT on new drug t...

UK-based biotech PhoreMost has begun a collaboration with India’s Centre for Chemical Biology (CCBT) and Therapeutics, focused on novel target sights for new drugs.

Catalyst’s rival to NovoSeven hits the mark in phase 2 haemo...

GSK takes aim at RA market, pitting otilimab against Pfizer ...

GlaxoSmithKline (GSK) has made a serious play for the lucrative rheumatoid arthritis (RA) drug market, announcing the beginning of a phase 3 development programme, involving a new class of

Roche's Tamiflu successor on target in phase 3 trial

A trial of Roche’s successor to flu medicine Tamiflu has met its goal in a phase 3 trial, with results showing that the new drug Xofluza is well tolerated in children with the flu.

Charity backs R&D into Parkinson's drugs targeting mitochond...

The charity Parkinson’s UK has struck a £1 million partnership with NRG Therapeutics to develop drugs targeted at mitochondria that could protect cells producing dopamine, which have been d